Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 813160

Next Previous
X
Search
Drug Profile

BMS 813160

Alternative Names: BMS-813160

Latest Information Update: 09 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Icahn School of Medicine at Mount Sinai; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antihyperglycaemics; Antineoplastics; Pyrazoles; Small molecules; Triazines; Uroprotectives
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Liver cancer; Non-small cell lung cancer
  • Phase I/II Adenocarcinoma; Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 25 Jul 2024 Bristol-Myers Squibb completes a phase I/II trial for Adenocarcinoma (Combination therapy, Late-stage disease) in USA (PO, Pill) (NCT03496662)
  • 16 Nov 2023 Bristol-Myers Squibb in collaboration with Icahn School of Medicine at Mount Sinai completes a phase II trial in Liver cancer and Non-small Cell Lung Cancer (Combination therapy, Neoadjuvant therapy) in USA (PO) (NCT04123379)
  • 14 Jun 2023 Bristol-Myers Squibb completes a Phase-I/II clinical trials in Colorectal cancer and Panceratic Cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA, Australia, Spain, Canada, Germany, Belgium (PO) (EudraCT2017-001725-40) (NCT03184870)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top